Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2015

View Archived Issues

Pfizer synthesizes new Abeta production inhibitors

Selective Nav1.7 inhibitors for the treatment of pain

IncellDx and Claremont to combine technologies for liquid-based biopsy system

JCR Pharma initiates development of ERT using BBB-crossing technology

Nanosyn and LLS update progress of MLL leukemia project

Piramal Enterprises presents BRD4 inhibitors

Sunshine Lake Pharma presents SGLT2 inhibitors

GDF15 may be a superior biomarker for mitochondrial disease diagnosis

Johnson & Johnson recaps highlights of first quarter 2015

Ombitasvir/paritaprevir/ritonavir HCV combination granted priority review in Japan

Avelas starts phase I trial of real-time fluorescent illuminator for breast cancer surgery

Baxter files for approval of BAX-855 in Japan

Isarna Therapeutics initiates first-in-human trial of ISTH-0036

Receptos's ozanimod achieves efficacy endpoints in phase II ulcerative colitis trial

TC-6499 fails to reduce gastric emptying time in diabetic gastroparesis study

Tipelukast receives FDA fast track designation for NASH with fibrosis

Actelion updates on clinical development of S1P1 receptor modulators

Discovery Laboratories advances development of Aerosurf, ceases commercialization of Surfaxin

World Hemophilia Day: Hyperfunctional FIX as a promising tool in hemophilia

Anacor reports boron-containing PDE4 inhibitors

Merck & Co. develops Trk-A inhibitors

FDA grants orphan drug designation to selumetinib for uveal melanoma

Chugai presents anti-protein-C MAbs

Provectus initiates phase III trial of PV-10 in melanoma

Genmab achieves fifth milestone in daratumumab collaboration with Janssen Biotech

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...